COMPASS Pathways plc (NASDAQ: CMPS) Given the average brokerage “buy” recommendation

Shares of COMPASS Pathways plc (NASDAQ: CMPS) received an average “buy” recommendation from the eight brokerages that currently cover the company, reports MarketBeat.com. One equity research analyst rated the stock with a conservation rating and seven issued a buy rating on the company. The 1-year average target price among brokers who updated their equity coverage in the past year is $ 79.86.

A number of research analysts have recently published reports on CMPS stocks. HC Wainwright raised its price target on COMPASS Pathways from $ 100.00 to $ 120.00 and gave the stock a “buy” rating in a report released on Monday, November 22. Oppenheimer began coverage of COMPASS Pathways in a report on Thursday, October 28. They set an “outperform” rating and a target price of $ 50.00 for the stock. Cantor Fitzgerald raised his price target on COMPASS Pathways from $ 71.00 to $ 82.00 and rated the stock “overweight” in a report released on Tuesday, November 9. They noted that the move was an appraisal call. Roth Capital raised its price target on COMPASS Pathways from $ 79.00 to $ 117.00 and gave the stock a “buy” rating in a report released on Tuesday, November 9. Finally, Zacks investment research upgraded COMPASS Pathways from a “sell” note to a “conservation” note in a research report published on Friday, November 12th.

A number of hedge funds and other institutional investors have recently changed their positions in CMPS. AGF Investments Inc. increased its position in COMPASS Pathways by 937,652.9% during the 3rd quarter. AGF Investments Inc. now owns 637,672 shares of the company valued at $ 19,047,000 after acquiring an additional 637,604 shares during the period. Logos Global Management LP strengthened its position in COMPASS Pathways by 240.0% during the 2nd quarter. Logos Global Management LP now owns 850,000 shares of the company valued at $ 32,428,000 after acquiring an additional 600,000 shares during the period. Wells Fargo & Company MN strengthened its position in COMPASS Pathways by 504.8% during the 2nd quarter. Wells Fargo & Company MN now owns 203,586 shares of the company valued at $ 7,766,000 after acquiring an additional 169,925 shares during the period. Oasis Management Co Ltd. purchased a new equity interest in COMPASS Pathways during the second quarter valued at approximately $ 6,024,000. Finally, Victory Capital Management Inc. increased its stake in COMPASS Pathways shares by 22.8% during the 2nd quarter. Victory Capital Management Inc. now owns 797,443 shares of the company valued at $ 30,423,000 after purchasing an additional 148,243 shares in the last quarter. Hedge funds and other institutional investors hold 17.86% of the company’s shares.

Actions of CMPS open at $ 23.00 Thursday. The stock’s fifty-day moving average is $ 33.33 and its 200-day moving average is $ 33.72. COMPASS Pathways has a one-year minimum of $ 21.20 and a one-year maximum of $ 60.87.

COMPASS Pathways (NASDAQ: CMPS) last released its results on Monday, November 8. The company reported ($ 0.38) earnings per share (EPS) for the quarter, beating analyst consensus estimates ($ 0.49) by $ 0.11. Sell-side analysts expect COMPASS Pathways to post -1.72 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc is a UK and US mental health care company. She is developing COMP360, a formulation of psilocybin that is in a Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was previously known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

Featured article: What are the causes of a recession?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in COMPASS Pathways now?

Before you consider COMPASS Pathways, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the wider market takes hold … and COMPASS Pathways was not on the list.

While COMPASS Pathways currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here